Given the role of IL1R1 in tumor progression, our findings suggest that preventing the binding of IL1α and its receptor by using antibodies against IL1α or IL1R1 could be new therapeutic strategies to reduce malignancy of TNBC. This evidence concerns the gene IL1A and neoplasm.